-
Posted by
Two Blokes Jun 8 -
Filed in
Stock
-
13 views
BioStem Technologies is a buy due to strong YoY growth, profitability, and undervaluation versus sector peers despite recent Q1 misses. Their advanced wound care products, powered by proprietary BioREtain technology, address a growing chronic wound market fueled by aging and diabetes trends. Balance sheet strength is notable, with assets outpacing liabilities and a rising cash position, supporting ongoing expansion and innovation.
